Global Health

Growth Hormone Releasing Factor Analog: Slimming Aid for Patients Receiving HAART?

Steven Grinspoon

Judith Currier

STEVEN GRINSPOON, Massachusetts General Hospital, Boston
COMMENT: JUDITH CURRIER, University of California, Los Angeles

REFERENCE: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007
Daily administration of an analog of growth hormone releasing factor to HIV patients receiving highly active antiretroviral therapy significantly decreased visceral fat and improved their lipid profiles. This development-stage drug, TH9507, was well tolerated and may help patients reduce central fat accumulation and abnormal lipid profiles, both of which are known cardiovascular risk factors. In addition, decreases in central fat may have a positive effect on patients’ self-image. Steven Grinspoon gave Dan Keller details during the 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles.

Similar Interviews

  • London School of Hygiene & Tropical Medicine Audio News Review, September 12th, 2007
  • Human Growth Hormone: Responses in Severe Heart Failure
  • Catherine Demers Recombinent human growth hormone has achieved clinical responses when used for treating heart failure. Catherine Demers of McMaster University

  • Sexual and Reproductive Health: The Global Challenge
  • Anna Glasier

    Post a comment

    Subscribe to Audio Medica Podcast